The antiviral treatment impacts on clinical outcomes of renal transplantation recipients with hepatitis B virus infection
10.3760/cma.j.issn.1003-9279.2009.03.021
- VernacularTitle:抗病毒治疗对乙型肝炎病毒感染者肾移植术后临床转归的影响
- Author:
Zhen-Wei WEI
1
;
Qi-Huan XU
;
Xin SHU
;
Yu-Sheng JIE
;
Ka ZHANG
;
Qi-Feng XIE
;
Gang LI
Author Information
1. 广西南宁市第四人民医院
- Keywords:
Kidney transplantation;
Hepatitis B viral;
Antiviral.treatment;
Liver function
- From:
Chinese Journal of Experimental and Clinical Virology
2009;23(3):224-226
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinic outcomes and the efficacy of antiviral treatment in renal transplantation recipients with hepatitis B viral serum markers positive. Methods 32 renal transplantation recipients with hepatitis B viral serum markers positive were enrolled. 23 patients in antiviral treatment group have received the lamivudine(19 cases),enticavir(2 cases) and adefovir(1 case). Another 9 patients have not received the antiviral treatment and were as the control group. Results The biochemical response rate in antiviral treatment group and control group is 82.60% and 22.22%, respectively. 19 of 23(82.60%) patients in treatment group survived and 1 of 9 (11.11%) patients in control group survived (P < 0.05). 20 of 23 (86.95%) patients in treatment group have the reduction of HBV DNA more than 2 log copies/ml or maintain less than 5 log copies/ml, while 1 of 9 (11.11%) patients in control group has the HBV DNA maintain less than 5 log copies/ml (P <0.05). The virology rebound was observed in 6 of 19(31.58%) patients with lamivudine treatment. 2 of them shift to enticavir treatment and 1 of them add adefovir treatment. The three patients survived. Other 3 patients die of liver function failure. Conclusion The antiviral could improve the survival in renal transplantation recipients with hepatitis B viral serum markers positive. When the virology rebound occurs, the add-on with adefovir or the shift to enticavir could be a rescue treatment.
